Rimegepant Appears Safe in Migraine Patients With Cardiovascular Risk ...Middle East

Medscape - News
Results from a 1-year, open-label safety study suggest that the oral migraine prevention drug rimegepant is safe and effective in patients with cardiovascular risk factors. Medscape Medical News

Hence then, the article about rimegepant appears safe in migraine patients with cardiovascular risk was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Rimegepant Appears Safe in Migraine Patients With Cardiovascular Risk )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News